title: Could coenzyme Q10 and L-carnitine be a treatment for diabetes secondary to 3243 mutation of mtDNA?
authors.forename: P
authors.initials: P
authors.lastname: Silvestre-Aillaud
authors.forename: D
authors.initials: D
authors.lastname: BenDahan
authors.forename: V
authors.initials: V
authors.lastname: Paquis-Fluckinger
authors.forename: J
authors.initials: J
authors.lastname: Pouget
authors.forename: J F
authors.initials: JF
authors.lastname: Pelissier
authors.forename: C
authors.initials: C
authors.lastname: Desnuelle
authors.forename: P J
authors.initials: PJ
authors.lastname: Cozzone
authors.forename: B
authors.initials: B
authors.lastname: Vialettes
mesh_terms: D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood; D002331:Carnitine / Q000627:therapeutic use*; D003067:Coenzymes; D004272:DNA, Mitochondrial / Q000235:genetics*; D003638:Deafness / Q000235:genetics; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D009682:Magnetic Resonance Spectroscopy; D008875:Middle Aged; D008931:Mitochondria, Muscle / Q000187:drug effects / Q000378:metabolism; D018482:Muscle, Skeletal / Q000473:pathology; D017354:Point Mutation; D012356:RNA, Transfer, Leu / Q000235:genetics*; D012173:Retinitis / Q000235:genetics; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D002331:Carnitine; D003067:Coenzymes; D004272:DNA, Mitochondrial; D006442:Glycated Hemoglobin; D007328:Insulin; D012356:RNA, Transfer, Leu; D014451:Ubiquinone; C024989:coenzyme Q10